Skip to Content

T. Rowe Price Integrated US LCV Eq Adv TQVAX

Medalist Rating as of | See T. Rowe Price Investment Hub
  • NAV / 1-Day Return 17.08  /  −0.23 %
  • Total Assets 34.4 Mil
  • Adj. Expense Ratio
    0.990%
  • Expense Ratio 0.990%
  • Distribution Fee Level Above Average
  • Share Class Type No Load
  • Category Large Value
  • Investment Style Large Value
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield 0.39%
  • Turnover 64%

USD | NAV as of Apr 17, 2024 | 1-Day Return as of Apr 17, 2024, 10:25 PM GMT+0

Morningstar’s Analysis TQVAX

Will TQVAX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

A lowering of People Pillar rating is the primary driver of T. Rowe Price Integrated US LCV Eq Adv's downgrade to a Morningstar Medalist Rating of Silver from Gold.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings TQVAX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 16.2
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

JPMorgan Chase & Co

3.10 1.1 Mil
Financial Services

Wells Fargo & Co

1.90 666,482
Financial Services

Exxon Mobil Corp

1.69 593,056
Energy

Citigroup Inc

1.59 559,548
Financial Services

Medtronic PLC

1.38 487,081
Healthcare

GE Aerospace

1.35 475,862
Industrials

Procter & Gamble Co

1.35 473,608
Consumer Defensive

Elevance Health Inc

1.32 465,649
Healthcare

The Cigna Group

1.29 454,714
Healthcare

iShares Russell 1000 Value ETF

1.27 445,984